What do systematic reviews say?

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings for the main comparison. Physical activity and exercise interventions vs usual care

• Physical activity interventions for people with congenital heart disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 163 participants
  Very low

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 249 participants
  Very low

Summary of findings table ‐ Rifaximin vs placebo or no intervention

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 214 participants
  Moderate

Summary of findings: Any alternative model of care vs usual care

Summary of findings: Any alternative model of care showed no clear difference in health‐related quality of life (mean difference) at longest compared with usual care (low certainty).

• Models for delivery and co‐ordination of primary or secondary health care (or both) to older adults living in aged… 2024 · Cochrane Headline outcomes only
  MD 0.016
  12 studies · 4016 participants
  Low

Summary of findings table ‐ Protein, arginine, zinc and antioxidants vs standard diet or placebo

The review found no eligible studies for this question.

• Nutritional interventions for preventing and treating pressure ulcers 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Minoxidil vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Very low

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 454 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1042 participants
  Very low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 870 participants
  Low

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1013 participants
  Low

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found